Last edition
News about "American Society of Clinical Oncology"
QureBio Reports Promising Phase Ib/II Data for Q-1802 in Advanced Gastric and GEJ Cancer
ASCO 2026 data show strong response rates and manageable safety for the bispecific antibody Q-1802 plus XELOX, supporting progression to a Phase III trial.
American Society Of Clinical Oncology | 29/01/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members